{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:26:30Z","timestamp":1769311590207,"version":"3.49.0"},"reference-count":115,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,6,25]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, are lipid-lowering agents that are central in preventing or reducing the complications of atherosclerotic cardiovascular disease. Because statins have anti-inflammatory properties, there is considerable interest in their therapeutic potential in other chronic inflammatory conditions. We aim to identify the statin with the greatest ability to reduce systemic inflammation, independent of the underlying disease entity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We aim to conduct a comprehensive search of published and peer-reviewed randomised controlled clinical trials, with at least one intervention arm of a Food &amp; Drug Administration-licensed or European Medicines Agency-licensed statin and a minimum treatment duration of 12 weeks. Our objective is to investigate the effect of statins (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin) on lipid profile, particularly, cholesterol low-density lipoprotein and inflammation markers such as high-sensitive C reactive protein (hsCRP), CRP, tumour necrosis factor alpha (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), IL-6, IL-8, soluble cluster of differentiation 14 (sCD14) or sCD16 in adults, published in the last 20 years (between January 1999 and December 2019). We aim to identify the most potent statin to reduce systemic inflammation and optimal dosing. The following databases will be searched: Medline, Scopus, Web of Science and Cochrane Library of Systematic Reviews. The risk of bias of included studies will be assessed by Cochrane Risk of Bias Tool and Quality Assessment Tool for Quantitative Studies. The quality of studies will be assessed, to show uncertainty, by the Jadad Score. If sufficient evidence is identified, a meta-analysis will be conducted with risk ratios or ORs with 95% CIs in addition to mean differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval is not required as no primary data will be collected. Results will be presented at conferences and published in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42020169919<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-039034","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T10:39:05Z","timestamp":1597401545000},"page":"e039034","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases"],"prefix":"10.1136","volume":"10","author":[{"given":"Solima","family":"Sabeel","sequence":"first","affiliation":[{"name":"International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town Component, Cape Town, South Africa"},{"name":"Institute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bongani","family":"Motaung","sequence":"additional","affiliation":[{"name":"International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town Component, Cape Town, South Africa"},{"name":"Institute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mumin","family":"Ozturk","sequence":"additional","affiliation":[{"name":"International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town Component, Cape Town, South Africa"},{"name":"Institute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Mukasa","sequence":"additional","affiliation":[{"name":"General Medicine & Global Health, Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Pascal","family":"Kengne","sequence":"additional","affiliation":[{"name":"South African Medical Research Council and University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Blom","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Sliwa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Nepolo","sequence":"additional","affiliation":[{"name":"University of Namibia School of Medicine, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunar","family":"G\u00fcnther","sequence":"additional","affiliation":[{"name":"University of Namibia School of Medicine, Windhoek, Namibia"},{"name":"Inselspital Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Francis Crick Institute, London NW1 1AT, United Kingdom"},{"name":"Department of Infectious Diseases, Imperial College London, London W12 0NN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Schacht","sequence":"additional","affiliation":[{"name":"LINQ management GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-2030","authenticated-orcid":false,"given":"Friedrich","family":"Thienemann","sequence":"additional","affiliation":[{"name":"General Medicine & Global Health, Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Department of Internal Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-2163","authenticated-orcid":false,"given":"Reto","family":"Guler","sequence":"additional","affiliation":[{"name":"International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town Component, Cape Town, South Africa"},{"name":"Institute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2025121515301747000_10.8.e039034.1","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.86.484"},{"key":"2025121515301747000_10.8.e039034.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2025121515301747000_10.8.e039034.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059344"},{"key":"2025121515301747000_10.8.e039034.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2001.tb00172.x"},{"key":"2025121515301747000_10.8.e039034.5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.65.070196.001325"},{"key":"2025121515301747000_10.8.e039034.6","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.163106"},{"key":"2025121515301747000_10.8.e039034.7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.45.120403.095748"},{"key":"2025121515301747000_10.8.e039034.8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00744.x"},{"key":"2025121515301747000_10.8.e039034.9","doi-asserted-by":"crossref","first-page":"1250-1260","DOI":"10.1002\/ijc.32426","article-title":"Statin use and risk of liver cancer: evidence from two population-based studies","volume":"146","author":"Tran","year":"2020","journal-title":"Int J Cancer"},{"key":"2025121515301747000_10.8.e039034.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-0984-3","article-title":"Effectiveness of long-term using statins in COPD - a network meta-analysis","volume":"20","author":"Lu","year":"2019","journal-title":"Respir Res"},{"key":"2025121515301747000_10.8.e039034.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2004.00299.x"},{"key":"2025121515301747000_10.8.e039034.12","doi-asserted-by":"publisher","DOI":"10.1042\/bj2650621"},{"key":"2025121515301747000_10.8.e039034.13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00754"},{"key":"2025121515301747000_10.8.e039034.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.1.64"},{"key":"2025121515301747000_10.8.e039034.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.01.023"},{"key":"2025121515301747000_10.8.e039034.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042378"},{"key":"2025121515301747000_10.8.e039034.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-015-0116-2"},{"key":"2025121515301747000_10.8.e039034.18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","volume":"31","author":"Toribio","year":"2017","journal-title":"AIDS"},{"key":"2025121515301747000_10.8.e039034.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00263-8"},{"key":"2025121515301747000_10.8.e039034.20","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960261507"},{"key":"2025121515301747000_10.8.e039034.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00430.x"},{"key":"2025121515301747000_10.8.e039034.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.010"},{"key":"2025121515301747000_10.8.e039034.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2011.09.009"},{"key":"2025121515301747000_10.8.e039034.24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/eci.12183","article-title":"The effect of statin therapy withdrawal on monocyte subsets","volume":"43","author":"Jaipersad","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"2025121515301747000_10.8.e039034.25","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0205064"},{"key":"2025121515301747000_10.8.e039034.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.10.015"},{"key":"2025121515301747000_10.8.e039034.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02505.x"},{"key":"2025121515301747000_10.8.e039034.28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.10.6259"},{"key":"2025121515301747000_10.8.e039034.29","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780115"},{"key":"2025121515301747000_10.8.e039034.30","first-page":"696","article-title":"Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients","volume":"25","author":"Lazzerini","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2025121515301747000_10.8.e039034.31","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039060-00002"},{"key":"2025121515301747000_10.8.e039034.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80336-3"},{"key":"2025121515301747000_10.8.e039034.33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2019.05.002","article-title":"Statin therapy among chronic kidney disease patients presenting with acute coronary syndrome","volume":"286","author":"Natanzon","year":"2019","journal-title":"Atherosclerosis"},{"key":"2025121515301747000_10.8.e039034.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215839","article-title":"Statin use in cirrhotic patients with infectious diseases: a population-based study","volume":"14","author":"Hung","year":"2019","journal-title":"PLoS One"},{"key":"2025121515301747000_10.8.e039034.35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.msard.2018.12.042","article-title":"Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin","volume":"28","author":"Lanzillo","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025121515301747000_10.8.e039034.36","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000319698.40024.1c"},{"key":"2025121515301747000_10.8.e039034.37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ajo.2015.01.009","article-title":"Association between statin use and uveitis: results from the Pacific ocular inflammation study","volume":"159","author":"Borkar","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2025121515301747000_10.8.e039034.38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/0886022X.2016.1256309","article-title":"Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients","volume":"39","author":"Tian","year":"2017","journal-title":"Ren Fail"},{"key":"2025121515301747000_10.8.e039034.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224111","article-title":"Effect of statin on life prognosis in Japanese patients undergoing hemodialysis","volume":"14","author":"Ota","year":"2019","journal-title":"PLoS One"},{"key":"2025121515301747000_10.8.e039034.40","article-title":"HMG CoA reductase inhibitors (statins) for dialysis patients","volume":"9","author":"Palmer","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121515301747000_10.8.e039034.41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/joim.12337","article-title":"Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial","volume":"278","author":"Neukamm","year":"2015","journal-title":"J Intern Med"},{"key":"2025121515301747000_10.8.e039034.42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-2600(14)70050-5","article-title":"Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial","volume":"2","author":"Mandal","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025121515301747000_10.8.e039034.43","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-17-0019"},{"key":"2025121515301747000_10.8.e039034.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203377","article-title":"Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: a two-stage database approach","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS One"},{"key":"2025121515301747000_10.8.e039034.45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jamaoncol.2017.2752","article-title":"Examining bias in studies of statin treatment and survival in patients with cancer","volume":"4","author":"Emilsson","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121515301747000_10.8.e039034.46","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.199"},{"key":"2025121515301747000_10.8.e039034.47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d6476a"},{"key":"2025121515301747000_10.8.e039034.48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228bf11"},{"key":"2025121515301747000_10.8.e039034.49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183765"},{"key":"2025121515301747000_10.8.e039034.50","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/pds.4052","article-title":"Association between statins and infections among patients with diabetes: a cohort and prescription sequence symmetry analysis","volume":"25","author":"Pouwels","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121515301747000_10.8.e039034.51","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16091626","article-title":"Association between statin use and sepsis risk in patients with dementia: a retrospective cohort study","volume":"16","author":"Yeh","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"2025121515301747000_10.8.e039034.52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3390\/jcm7110381","article-title":"Statin for tuberculosis and pneumonia in patients with Asthma\u207bChronic pulmonary disease overlap syndrome: a time-dependent population-based cohort study","volume":"7","author":"Yeh","year":"2018","journal-title":"J Clin Med"},{"key":"2025121515301747000_10.8.e039034.53","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.chest.2017.04.170","article-title":"Statin use is associated with a lower risk of TB","volume":"152","author":"Su","year":"2017","journal-title":"Chest"},{"key":"2025121515301747000_10.8.e039034.54","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207052"},{"key":"2025121515301747000_10.8.e039034.55","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit550"},{"key":"2025121515301747000_10.8.e039034.56","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41577-018-0094-3","article-title":"Statins: a viable candidate for host-directed therapy against infectious diseases","volume":"19","author":"Parihar","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"2025121515301747000_10.8.e039034.57","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"2025121515301747000_10.8.e039034.58","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/j.1552-4604.1997.tb05629.x","article-title":"Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin","volume":"37","author":"Stern","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"2025121515301747000_10.8.e039034.59","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00045-5"},{"key":"2025121515301747000_10.8.e039034.60","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.1.3.207"},{"key":"2025121515301747000_10.8.e039034.61","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04194.x"},{"key":"2025121515301747000_10.8.e039034.62","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90218-0"},{"key":"2025121515301747000_10.8.e039034.63","first-page":"255","article-title":"Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin","volume":"35","author":"M\u00fcck","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025121515301747000_10.8.e039034.64","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/j.1552-4604.1995.tb04065.x","article-title":"No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin","volume":"35","author":"Schall","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"2025121515301747000_10.8.e039034.65","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050566"},{"key":"2025121515301747000_10.8.e039034.66","unstructured":"Bayer . BAYCOL (cerivastatin sodium tablets), 1997."},{"key":"2025121515301747000_10.8.e039034.67","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00717.x"},{"key":"2025121515301747000_10.8.e039034.68","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb05773.x"},{"key":"2025121515301747000_10.8.e039034.69","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199631050-00003"},{"key":"2025121515301747000_10.8.e039034.70","doi-asserted-by":"crossref","first-page":"375S","DOI":"10.1093\/ajh\/6.11.375S","article-title":"Pharmacokinetics of fluvastatin and specific drug interactions","volume":"6","author":"Smith","year":"1993","journal-title":"Am J Hypertens"},{"key":"2025121515301747000_10.8.e039034.71","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732050-00005"},{"key":"2025121515301747000_10.8.e039034.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90145-9"},{"key":"2025121515301747000_10.8.e039034.73","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000127"},{"key":"2025121515301747000_10.8.e039034.74","doi-asserted-by":"publisher","DOI":"10.1177\/107424840100600205"},{"key":"2025121515301747000_10.8.e039034.75","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(05)80026-8"},{"key":"2025121515301747000_10.8.e039034.76","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00034.x"},{"key":"2025121515301747000_10.8.e039034.77","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb03818.x"},{"key":"2025121515301747000_10.8.e039034.78","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2125.1991.tb05590.x","article-title":"Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin","volume":"31","author":"Pan","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"2025121515301747000_10.8.e039034.79","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90626-2"},{"key":"2025121515301747000_10.8.e039034.80","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/j.1552-4604.1990.tb01856.x","article-title":"Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin","volume":"30","author":"Pan","year":"1990","journal-title":"J Clin Pharmacol"},{"key":"2025121515301747000_10.8.e039034.81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpba.2012.09.026","article-title":"Simple LC-MS\/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study","volume":"72","author":"Qi","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"2025121515301747000_10.8.e039034.82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01071.x"},{"key":"2025121515301747000_10.8.e039034.83","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1554-0"},{"key":"2025121515301747000_10.8.e039034.84","first-page":"34","article-title":"The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects","volume":"46","author":"Shang","year":"2016","journal-title":"Xenobiotica"},{"key":"2025121515301747000_10.8.e039034.85","unstructured":"Kowa . LIVALO\u00ae (pitavastatin) tablet, 2016."},{"key":"2025121515301747000_10.8.e039034.86","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.curtheres.2015.02.001","article-title":"Pharmacokinetic properties of single- and multiple-dose pitavastatin calcium tablets in healthy Chinese volunteers","volume":"77","author":"Luo","year":"2015","journal-title":"Curr Ther Res Clin Exp"},{"key":"2025121515301747000_10.8.e039034.87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02462.x"},{"key":"2025121515301747000_10.8.e039034.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.03.027"},{"key":"2025121515301747000_10.8.e039034.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.013"},{"key":"2025121515301747000_10.8.e039034.90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2006.05.010"},{"key":"2025121515301747000_10.8.e039034.91","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.clinthera.2007.10.005","article-title":"Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study","volume":"29","author":"Li","year":"2007","journal-title":"Clin Ther"},{"key":"2025121515301747000_10.8.e039034.92","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1801-z"},{"key":"2025121515301747000_10.8.e039034.93","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1800-0"},{"key":"2025121515301747000_10.8.e039034.94","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80316-8"},{"key":"2025121515301747000_10.8.e039034.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2006.04.015"},{"key":"2025121515301747000_10.8.e039034.96","doi-asserted-by":"crossref","first-page":"28B","DOI":"10.1016\/S0002-9149(01)01454-0","article-title":"Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"87","author":"McTaggart","year":"2001","journal-title":"Am J Cardiol"},{"key":"2025121515301747000_10.8.e039034.97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03626.x"},{"key":"2025121515301747000_10.8.e039034.98","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00052-3"},{"key":"2025121515301747000_10.8.e039034.99","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01972.x"},{"key":"2025121515301747000_10.8.e039034.100","first-page":"70","article-title":"Comparative study on the bioequivalence of two formulations of pravastatin. data from a crossover, randomised, open-label bioequivalence study in healthy volunteers","volume":"56","author":"Almeida","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"2025121515301747000_10.8.e039034.101","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003257232"},{"key":"2025121515301747000_10.8.e039034.102","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022008874"},{"key":"2025121515301747000_10.8.e039034.103","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.curtheres.2005.06.001","article-title":"Pharmacokinetic properties of pravastatin in Mexicans: an open-label study in healthy adult volunteers","volume":"66","author":"Escobar","year":"2005","journal-title":"Curr Ther Res Clin Exp"},{"key":"2025121515301747000_10.8.e039034.104","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199324030-00002"},{"key":"2025121515301747000_10.8.e039034.105","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X167471"},{"key":"2025121515301747000_10.8.e039034.106","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s13318-015-0263-8","article-title":"Pomegranate juice does not affect the disposition of simvastatin in healthy subjects","volume":"41","author":"Park","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2025121515301747000_10.8.e039034.107","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601152"},{"key":"2025121515301747000_10.8.e039034.108","unstructured":"Merck . ZOCOR (simvastatin) tablets, 1991."},{"key":"2025121515301747000_10.8.e039034.109","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111414"},{"key":"2025121515301747000_10.8.e039034.110","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0700-5"},{"key":"2025121515301747000_10.8.e039034.111","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90165-5"},{"key":"2025121515301747000_10.8.e039034.112","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104609"},{"key":"2025121515301747000_10.8.e039034.113","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90130-8"},{"key":"2025121515301747000_10.8.e039034.114","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.108507"},{"key":"2025121515301747000_10.8.e039034.115","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s11095-007-9519-6","article-title":"Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms","volume":"25","author":"Tubic-Grozdanis","year":"2008","journal-title":"Pharm Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-039034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T23:30:30Z","timestamp":1765841430000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-039034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":115,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2020-039034"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-039034","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}